Citius pharmaceuticals announces positive results from the phase 2b study of halo-lido (citi-002) for the treatment of hemorrhoids

Citi-002 provides a meaningful reduction in symptom severity when compared to individual components alone dose for phase 3 trial selected; citius to schedule end of phase 2 meeting with the fda trial validates patient reported outcome (pro) instrument developed to support a pivotal phase 3 study  cranford, n.j. , june 20, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr) today announced results from the company's phase 2b clinical study of halo-lido (citi-002), a topical formulation for the relief of hemorrhoid symptoms.
CTXR Ratings Summary
CTXR Quant Ranking